ReviewThe Lancet. Infectious diseases2021
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
Review in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis.American journal of epidemiology · 2024Pooled it
- Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months.The Journal of clinical investigation · 2022Trial
- Accelerating the approval of mpox vaccines based on lessons learnt from COVID-19 vaccines through the lens of regulatory science.BMJ global health · 2025Review
- Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.Mayo Clinic proceedings. Innovations, quality & outcomes · 2025Article
- Mucosal Vaccination Against SARS-CoV-2 Using Human ProbioticVaccines · 2025Article
- Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study.Vaccines · 2024Article
- Expediting approval for medical countermeasures to address high burden disease: an ethical justification to move beyond emergency use authorisation.BMJ global health · 2023Review
- Key ethical issues encountered during COVID-19 research: a thematic analysis of perspectives from South African research ethics committees.BMC medical ethics · 2023Article
- Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness.International journal of environmental research and public health · 2023Article
- "We are Tired but Do Not Give Up" the Dilemma and Challenges of Primary Nurses Facing the Omicron Variant: Qualitative Research.Journal of multidisciplinary healthcare · 2023Article
- Effect of vaccination against Covid-19 one year after its introduction in Brazil.Tropical diseases, travel medicine and vaccines · 2022Article
- COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS).BMC women's health · 2022Article
- Natural inhibitors of SARS-CoV-2 main protease: structure based pharmacophore modeling, molecular docking and molecular dynamic simulation studies.Journal of molecular modeling · 2022Article
- A Thorough Synthesis of Phage Therapy Unit Activity in Poland-Its History, Milestones and International Recognition.Viruses · 2022Article
- Review
- Review
- A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.Frontiers in immunology · 2022Article
- Cost-utility-safety analysis of alternative intradermal versus classical intramuscular COVID-19 vaccination.International journal of physiology, pathophysiology and pharmacology · 2022Article
- Safety, effectiveness and hesitancy of COVID-19 vaccination in children: A cross-sectional study in Pakistan.Frontiers in public health · 2022Article
- Using a health belief model to assess COVID-19 vaccine intention and hesitancy in Jakarta, Indonesia.PLOS global public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An efficacious COVID-19 vaccine is currently the world's leading research priority. Several nations have indicated that if there is a compelling case for use of a vaccine before it is licensed, they would be prepared to authorise its emergency use or conditional approval on public health grounds. As of Dec 1, 2020, several developers of leading COVID-19 candidate vaccines have indicated that they have applied, or intend to apply, for emergency authorisation for their vaccines. Should candidate vaccines attain emergency use designation and be programmatically deployed before their phase 3 trials conclude, such a strategy could have far reaching consequences for COVID-19 vaccine research and the effective control of the COVID-19 pandemic. These issues merit careful consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.